THURSDAY, Jan. 26, 2023 (HealthDay News) — Bivalent vaccines seem to provide additional protection against symptomatic BA.5 and XBB/XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron sublineages, according to research published in the Jan. 27 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Ruth Link-Gelles, Ph.D., from the CDC in Atlanta, and colleagues analyzed data from the Increasing Community Access to Testing national pharmacy program for SARS-CoV-2 testing to estimate the vaccine effectiveness of updated (bivalent) mRNA COVID-19 vaccines against symptomatic infection caused by BA.5-related and XBB/XBB.1.5-related sublineages among adults during Dec. 1, 2022, to Jan. 13, 2023. A total of 29,175 nucleic acid amplification tests were included from adults who had previously received two to four monovalent COVID-19 vaccine doses.
People are also reading…
The researchers found that for adults aged 18 to 49 years, the relative vaccine effectiveness of a bivalent booster given two to three months earlier was 52 and 48 percent against symptomatic BA.5 infection and against symptomatic XBB/XBB.1.5 infection, respectively, compared with no bivalent booster.
“All persons should stay up to date with recommended COVID-19 vaccines, including receiving a bivalent booster dose when eligible,” the authors write.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
